JANLOTCServices-Business Services, NECUS GAAP · USD

Janel Corp

Janel Corp is a U.S.-based holding company with operating subsidiaries in logistics, life sciences, and manufacturing. It creates value by allocating capital across these businesses, supporting organic growth, and acquiring companies that fit its portfolio and management style.

Liikevaihto207milj. USD
+13,2 %v/v
Liikevoitto (EBIT)6,4milj. USD
+71,2 %v/v
EBIT-marginaali3,1%
+1,1 %-yks.v/v
Nettotulos5,7milj. USD
+926,7 %v/v
Vapaa kassavirta43,1milj. USD
+530,4 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−1000100200300400milj. USD2020: 82 milj. USD2020: EBIT −1,7 milj. USD20202021: 146 milj. USD2021: EBIT 4,0 milj. USD20212022: 317 milj. USD2022: EBIT 9,5 milj. USD20222023: 186 milj. USD2023: EBIT 2,6 milj. USD20232024: 183 milj. USD2024: EBIT 3,8 milj. USD20242025: 207 milj. USD2025: EBIT 6,4 milj. USD20252076,4
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Logistics services85 %

Non-asset-based cargo transportation management, including forwarding, brokerage, warehousing, trucking, and accessorial charges.

Life sciences products10 %

Protein-related research and diagnostic reagents sold to scientific and clinical customers.

Manufacturing5 %

Industrial/manufacturing activities and related products within the portfolio.

Tuotteet

Raportoitu · osuus liikevaihdosta
88,6%11,4%FY2025100 %
  • Logistics88,6 %
  • Life Sciences and Manufacturing11,4 %

Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.

Asiakkaat

Janel serves a broad logistics customer base that uses freight forwarding, customs brokerage, and warehousing to move goods efficiently across modes and borders. Its life sciences customers include academic, diagnostic, and pharmaceutical research users that buy reagents for research and testing workflows. The company also sells to customers that value its scientific expertise and may re-label products, while logistics customers range from diversified shippers to businesses needing flexible, non-asset-based transport solutions.

Logistics shippers

Businesses shipping freight domestically and internationally that buy forwarding, brokerage, warehousing, and trucking services to reduce complexity and transit time.

Academic and research institutions

Universities and research labs buying protein-related reagents and tools for life science research.

Diagnostic and pharmaceutical customers

Clinical and pharma buyers using reagents and scientific products for testing, development, and research workflows.

Private-label / re-label customers

Customers that use Janel's scientific expertise and production capabilities to source products under their own brand.

Strategia

Janel's strategy centers on disciplined capital allocation, organic growth, and acquisitions that add stable earnings power. Management also emphasizes operational improvement, talent retention, and product innovation, especially in life sciences, to strengthen profitability and expand the portfolio over time.

Acquisitions and portfolio expansionKeskipitkä aikaväli

Janel expects growth from buying businesses within existing segments or entering new ones.

Operational improvementLyhyt aikaväli

Better operating design and processes can lift profitability and free capital for growth.

Product innovation in life sciencesKeskipitkä aikaväli

New products can broaden the research toolkit and deepen customer relationships.

Maantiede

Janel is headquartered in New York and operates primarily in the United States, where it employed all 353 full-time employees as of fiscal 2025. Its logistics segment also serves international trade lanes through a network of independent agents in many trading countries, so a meaningful part of the business is exposed to cross-border freight flows. The company does not disclose a country-level revenue split in the provided excerpts, but its logistics activity is clearly global in scope.

Riskit

Janel's growth model depends heavily on acquisitions, so deal sourcing, integration, and valuation discipline are central risks. Its logistics business is exposed to trade disruption, cybersecurity, and third-party system failures, while the life sciences business faces competitive pressure and product-development execution risk. Because the company uses a holding-company structure, performance also depends on how well capital is allocated across subsidiaries and whether acquired earnings prove durable.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Geopolitical and trade disruption1Acquisition execution and valuation risk2Cybersecurity and IT systems risk3Third-party provider dependence4
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Geopolitical and trade disruptionVaikutus: KorkeaTodennäköisyys: Korkea

    Logistics volumes and routing can be affected by war, terrorism, and border/security changes.

    Kohdistuu: Most relevant to freight forwarding and cross-border shipments.

  2. Acquisition execution and valuation riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    Growth depends on buying businesses at reasonable prices and integrating them successfully.

    Kohdistuu: Could reduce profitability if targets underperform or synergies do not materialize.

  3. Cybersecurity and IT systems riskVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company relies on internal and third-party systems to manage shipments and sensitive data.

    KohdistuuCould cause service interruptionsLiabilityReputational damage
  4. Third-party provider dependenceVaikutus: KeskitasoTodennäköisyys: Korkea

    Janel is non-asset-based and relies on carriers, agents, and vendors to execute shipments.

    Kohdistuu: Service quality and margins depend on external partners.

Kirjanpito

Harkinnanvaraiset erät
Acquisition-related intangible assets

Purchased customer relationships and other intangibles create amortization that reduces reported earnings.

Vaikutus: Can materially affect operating income and net income after acquisitions.

Organic revenue and gross profit measures

Management excludes recent acquisitions to show underlying performance.

Vaikutus: Important for comparing periods, especially after deal activity.

Non-GAAP adjusted operating income

This measure excludes items not in GAAP and may present a different profitability trend.

Vaikutus: Can influence investor perception of core operating performance.

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Päivitetty: 24.9.2026